Latest CANCER TREATMENT News | Top CANCER TREATMENT News Headlines Today | Today India news | Breaking CANCER TREATMENT News Today | English CANCER TREATMENT News Headlines - TheDailyGuardian

King Charles Undergoes Hospital Observation Amid Cancer Treatment

March 28, 2025, 1:41 pm

King Charles was briefly hospitalized on Thursday due to temporary side effects from his ongoing cancer treatment, Buckingham Palace announced. The 76-year-old monarch underwent scheduled treatment in the morning, which required a short period of hospital observation. The palace reassured the public that the king had since returned to Clarence House and was in good spirits.

The side effects were described as temporary and not uncommon in medical treatments. As a precaution, Charles postponed his Friday engagements and rescheduled his diary upon medical advice. The palace expressed the king’s regret at any inconvenience caused to those affected by the postponements. A palace spokesperson stated, “His Majesty has now returned to Clarence House and, acting on medical advice, tomorrow’s diary programme will also be rescheduled.”

A royal source characterized the health concern as a “minor bump in a road that is very much heading in the right direction.” Despite his condition, the king has maintained an active schedule. Diagnosed with an undisclosed form of cancer in February 2024, he resumed public duties in April while continuing weekly treatment. This week, he attended multiple engagements, including a media reception and a soil exhibition visit. He is also preparing for a historic state visit to Italy, where he is set to be the first British sovereign to address both houses of the Italian parliament. The trip, scheduled in ten days, is expected to proceed as planned.

Before the hospitalization, King Charles had been scheduled to meet ambassadors at Buckingham Palace on Thursday afternoon and to travel to Birmingham for four public engagements on Friday. These have been postponed as a precautionary measure, as recommended by his medical team.

The king’s brief hospital visit took place at the London Clinic, where he had previously received treatment for an enlarged prostate in January 2024. He traveled alone and was not accompanied by Queen Camilla. Following the observation period, he returned home in good form, continuing his official work, including reviewing state documents and making phone calls from his study.

Buckingham Palace clarified that the king was disappointed about postponing his planned engagements and expressed gratitude to those involved in organizing them. “His Majesty was due to receive credentials from ambassadors of three different nations this afternoon. Tomorrow he was due to undertake four public engagements in Birmingham and is greatly disappointed to be missing them on this occasion. He very much hopes that they can be rescheduled in due course and offers his deepest apologies to all those who had worked so hard to make the planned visit possible.”

The decision to announce the hospitalization late on Thursday was made to allow the king time to consult with his staff and medical advisors after returning to Clarence House. His schedule and health status continue to be closely monitored by his medical team to ensure his recovery remains a priority.

Since his diagnosis last year, King Charles’ public engagements have been carefully planned with his doctors to avoid any strain on his health. While his condition is managed, the palace has been keen on maintaining transparency regarding his well-being. The latest hospital visit was considered a precautionary measure rather than a significant development in his treatment.

Sources indicated that no further updates on his condition are expected at this time. Any minor adjustments to his engagements next week will be announced as necessary. The approach underscores the palace’s ongoing commitment to balancing the king’s duties with his health requirements.

King Charles ascended to the throne on September 8, 2022, following the passing of his mother, Queen Elizabeth II. His reign has been marked by efforts to modernize the monarchy and maintain continuity during a time of transition. When his cancer diagnosis was made public in February 2024, Buckingham Palace requested privacy regarding specific details, revealing only that it was a “form of cancer.”

His condition was detected during treatment for a benign prostate condition when a separate issue of concern was identified and investigated. In December 2024, an official statement indicated that his treatment had been progressing positively and was expected to continue as a managed condition into 2025.

Despite health challenges, King Charles has shown resilience and dedication to his royal duties. In December 2024, during a public visit to Walthamstow in northeast London, he was asked about his health and responded with a smile, saying, “I’m still alive.” His ability to maintain humor and composure despite his illness has been noted by supporters and royal watchers.

The king’s continued engagement with his responsibilities, including his anticipated visit to Italy, reflects his commitment to serving the nation. While some scheduling adjustments may be necessary, his medical team remains optimistic about his overall progress. Royal insiders emphasize that the recent hospitalization was a routine step rather than a cause for alarm.

As the king focuses on his recovery, public support and well-wishes continue to pour in. The British public, alongside international well-wishers, has expressed admiration for his perseverance and dedication. While his engagements are being carefully managed, there is optimism that he will continue fulfilling his royal duties while receiving the necessary medical care.

Buckingham Palace has assured the public that the king remains in good spirits and is actively involved in his responsibilities, despite temporary health setbacks. Any further updates on his condition will be shared as needed, but the prevailing sentiment is one of cautious optimism. His upcoming engagements will be reviewed on a case-by-case basis to ensure his health remains the top priority.

King Charles’ brief hospital stay highlights the complexities of managing a high-profile role while undergoing cancer treatment. His ability to balance medical care with his commitments demonstrates both his dedication to his duties and the importance of prioritizing health. As he continues his treatment, his resilience and determination remain central to his role as monarch.

New Antibody Therapy: A Game-Changer in Cancer Treatment

March 18, 2025, 1:36 pm

Cancer treatment has seen remarkable advancements over the years, from radiation and chemotherapy to targeted therapy and immunotherapy. Yet, despite these breakthroughs, chemotherapy remains one of the most commonly used treatments for cancer. However, a groundbreaking discovery in antibody therapy could revolutionize cancer treatment by replacing chemotherapy with a more targeted and less toxic approach.

Recent research has unveiled a promising antibody therapy that directly targets cancer cells while sparing healthy tissues. Scientists believe this new treatment could drastically reduce the side effects associated with chemotherapy, such as nausea, hair loss, and weakened immunity. If successful, it could be a game-changer in oncology, improving survival rates and patients’ quality of life.

The Challenges of Chemotherapy

Chemotherapy has been a cornerstone of cancer treatment for decades, using powerful drugs to kill rapidly dividing cancer cells. However, it also affects healthy cells that divide quickly, such as those in the hair follicles, digestive tract, and bone marrow. This leads to severe side effects, including:

Hair loss
Nausea and vomiting
Fatigue
Suppressed immune function
Increased risk of infections
Organ damage

While chemotherapy is effective in shrinking tumors and eliminating cancer cells, it often weakens the body, making recovery difficult. Additionally, some cancers develop resistance to chemotherapy over time, reducing its effectiveness. This is why researchers have been searching for a better alternative—one that specifically targets cancer cells without harming the rest of the body.

What Is Antibody Therapy?

Antibody therapy, also known as monoclonal antibody (mAb) therapy, is a form of targeted cancer treatment that harnesses the power of the immune system. Unlike chemotherapy, which indiscriminately attacks all rapidly dividing cells, antibody therapy is designed to seek out and destroy only cancer cells.

Antibodies are proteins that the immune system naturally produces to fight infections. Scientists can create artificial antibodies that specifically recognize markers on cancer cells, allowing them to bind to and neutralize the tumor while leaving healthy cells unharmed.

Some of the ways antibody therapy works include:

Blocking Growth Signals – Certain cancer cells grow uncontrollably due to abnormal signaling pathways. Antibody therapy can block these signals, preventing the tumor from expanding.
Tagging Cancer Cells for Destruction – Some antibodies mark cancer cells so that the immune system can recognize and destroy them.
Delivering Toxins Directly to Tumors – Some antibody therapies are linked to drugs or radiation that directly kill cancer cells upon binding.

The New Antibody Therapy: A Breakthrough Discovery

A recent study has identified a powerful new antibody therapy that could replace chemotherapy altogether. This therapy, developed by a team of scientists, targets a specific protein found only on the surface of cancer cells.

When administered, the antibody binds to cancer cells and prevents them from multiplying. Additionally, it stimulates the immune system to attack and destroy these cells more efficiently. Early clinical trials have shown promising results, with significantly fewer side effects compared to chemotherapy.

How the New Antibody Therapy Works

The newly developed antibody therapy operates in several ways:

Selective Targeting: It binds exclusively to tumor cells, preventing collateral damage to healthy tissues.
Immune System Boosting: It enhances the body’s natural ability to detect and destroy cancer.
Reduced Resistance: Unlike chemotherapy, which cancer cells can become resistant to, antibody therapy maintains its effectiveness over time.

Clinical Trials and Results

Early-stage trials involving patients with aggressive cancers such as lung, breast, and colon cancer have shown remarkable improvements. Some key findings include:

A significant reduction in tumor size in over 70% of patients.
Longer survival rates compared to those receiving chemotherapy.
Fewer side effects, with patients reporting less fatigue and nausea.

These promising results have led to further research and larger trials to determine whether this therapy can become a standard treatment option.

Advantages of Antibody Therapy Over Chemotherapy

The shift from chemotherapy to antibody therapy could bring several benefits, including:

Fewer Side Effects – Because antibody therapy targets only cancer cells, it does not harm healthy tissues, resulting in a much better quality of life for patients.
More Effective Tumor Control – The precision of antibody therapy reduces the risk of tumors developing resistance.
Improved Immune Response – Some antibody treatments train the immune system to fight cancer more effectively, potentially preventing recurrence.
Combination Potential – Antibody therapy can be combined with other treatments like immunotherapy, radiation, or surgery for even better results.

The Future of Cancer Treatment

While this new antibody therapy is still undergoing trials, researchers are optimistic that it could replace chemotherapy as the first-line treatment for many cancers. If approved for widespread use, it could redefine how oncologists approach cancer care.

Additionally, scientists are working on developing similar antibody treatments for other types of cancer, including pancreatic and brain tumors. The goal is to create therapies that are not only effective but also safe and accessible for patients worldwide.

Challenges and Considerations

Despite the promising outlook, there are still challenges to address before antibody therapy can fully replace chemotherapy:

Cost and Accessibility – Antibody therapies can be expensive to develop and manufacture, which may limit access for some patients.
Long-Term Effects – While short-term benefits are evident, more studies are needed to understand the long-term impact.
Not a One-Size-Fits-All Solution – Some cancers may respond better to antibody therapy than others, making personalized treatment crucial.

The development of antibody therapy as a potential replacement for chemotherapy marks a revolutionary step forward in cancer treatment. By offering a targeted, less toxic alternative, this breakthrough has the potential to save millions of lives while minimizing the harsh side effects of traditional chemotherapy.

As research continues, this innovative therapy could redefine how cancer is treated, providing hope for patients and their families. While challenges remain, the future of oncology looks brighter than ever, thanks to advances in targeted antibody treatments.

Cancer Treatment Delays Soar in England: A Growing Crisis

February 15, 2025, 1:53 pm

In recent years, the healthcare system in England has faced increasing challenges, particularly in the realm of cancer care. With rising numbers of cancer patients and significant delays in treatment, the situation has become a critical issue. Recent figures reveal that more than 11% of cancer patients in England had to wait longer than 104 days for treatment in 2024, a sharp increase from 4.4% in 2016. This surge is a stark reminder of the growing crisis in cancer services and the urgent need for action.

A Troubling Trend: The Escalating Wait Times

According to an analysis by Cancer Research UK, the number of cancer patients waiting more than 104 days for treatment has nearly quadrupled over the past seven years. In 2016, just over 6,000 patients experienced these long waits, but by 2024, this number had skyrocketed to 22,000. The data shows that the problem is not only growing but worsening, with more patients being forced to wait for extended periods before receiving the treatment they desperately need.

These delays are concerning because cancer is a time-sensitive disease. Early intervention and timely treatment are crucial for improving survival rates and preventing the disease from progressing. The longer a patient waits for treatment, the higher the risk that the cancer will spread, leading to more complicated and potentially less treatable cases. Furthermore, delays in treatment can significantly reduce the chances of successful outcomes, especially for aggressive cancers.

The Strain on the NHS: A System Under Pressure

One of the primary factors contributing to the delays in cancer treatment is the overwhelming pressure on the National Health Service (NHS). The NHS has been under stress for years, grappling with increasing demand and underfunding. The situation has worsened in recent times, as the healthcare system is struggling to meet the needs of an aging population and a rising number of cancer diagnoses.

Despite the best efforts of healthcare workers, the NHS has not been able to meet its targets for treating cancer patients on time. The target is to treat 85% of cancer patients within 62 days of an urgent referral, but this has not been achieved since December 2015. Even when patients are referred through screening or by a consultant, nearly one-third of them are still not treated within the required time frame. This failure to meet targets has been a source of concern for both cancer patients and healthcare professionals, who are frustrated by the lack of progress.

The Impact of Delays on Cancer Survival Rates

Delays in cancer treatment can have a significant impact on survival rates. Studies have shown that every four-week delay in treatment can increase the risk of death by 10%, particularly for aggressive cancers such as lung, pancreatic, and colorectal cancer. For patients with these types of cancer, a delay in treatment can make the difference between life and death. This is why timely intervention is so crucial for improving outcomes and ensuring that patients have the best possible chance of survival.

In addition to the physical toll on patients, long waiting times also take a psychological toll. The uncertainty and anxiety of waiting for treatment can be overwhelming, leading to mental health issues such as depression and anxiety. Patients and their families are left in limbo, unsure of what the future holds and whether their treatment will be effective. This emotional strain can be just as damaging as the physical effects of cancer itself.

The Government’s Response: The Cancer Plan

In an attempt to address the growing crisis in cancer services, the UK government recently relaunched its national cancer plan. This plan aims to improve cancer care by addressing waiting times, increasing access to treatment, and ensuring that patients receive timely diagnoses. However, many experts and charity organizations have expressed concern that the plan is not enough to tackle the scale of the problem.

Michelle Mitchell, the chief executive of Cancer Research UK and a representative of One Cancer Voice, a coalition of more than 50 cancer charities, has stated that the slow rate of improvement in treatment times is not good enough. While the government’s plan is a step in the right direction, experts argue that without significant investment in staff and equipment, the plan will fail to meet its targets.

The need for additional funding is clear. The NHS is facing a severe shortage of staff, particularly in oncology, and this is contributing to the delays in cancer treatment. The government must invest in recruiting more healthcare professionals, as well as providing additional resources to ensure that existing staff are not overwhelmed by the rising demand for services. Without these investments, the healthcare system will continue to struggle, and cancer patients will bear the brunt of the crisis.

Marginal Improvements: A Glimmer of Hope?

Despite the challenges, there have been some improvements in cancer care. According to NHS data, the percentage of patients treated within 62 days of an urgent referral showed a slight improvement in December 2024, rising to 66.4% from 64.5% in November. While this increase is positive, it is still far from the target of 85%. Furthermore, nearly one-third of patients are still not being treated within the required time frame, highlighting the need for further efforts to address the issue.

In addition, the number of patients receiving a definitive cancer diagnosis within 28 days of referral has improved, with 78.1% of people receiving the all-clear or a diagnosis in a timely manner. This is an important step forward, as early diagnosis is key to improving cancer survival rates. However, experts caution that these marginal improvements should not be used to mask the ongoing crisis in cancer treatment. The fact remains that thousands of patients are still waiting too long for treatment, and this must be addressed urgently.

The Role of Early Diagnosis and Screening

Early diagnosis and screening play a critical role in improving cancer outcomes. The sooner cancer is detected, the sooner treatment can begin, and the better the chances of a successful outcome. In recent years, the number of urgent referrals for suspected cancer has more than doubled, and more people than ever are being diagnosed at an early stage. This is a positive trend, as early-stage cancers are often easier to treat and have better survival rates.

However, despite these improvements in early detection, delays in treatment remain a significant issue. Even when cancer is diagnosed early, patients are often left waiting months for treatment. This highlights the need for a comprehensive approach to cancer care that includes not only early diagnosis but also timely access to treatment. If the NHS can address the issue of waiting times, it will significantly improve cancer survival rates and reduce the emotional and physical toll on patients.

The Call for Immediate Action

Experts agree that urgent action is needed to address the crisis in cancer treatment. Prof Pat Price, a leading oncologist and chair of Radiotherapy UK, has emphasized that thousands of lives are at risk because of the normalization of delays in cancer treatment. Every month of delay in treatment increases the risk of death, and the longer patients wait, the less likely they are to survive.

Prof Price and other healthcare professionals are calling for a monumental effort from the government to address the issue. This includes increasing funding for cancer services, improving access to treatment, and ensuring that patients are treated in a timely manner. Without these changes, the NHS will continue to struggle, and cancer patients will continue to suffer the consequences.

In conclusion, the rise in cancer patients waiting months for treatment in England is a critical issue that requires immediate attention. While there have been some improvements in cancer care, the overall situation remains dire. Thousands of patients are still waiting too long for treatment, and this is impacting their chances of survival. The government must take decisive action to address the issue by investing in staff, equipment, and resources. Until these changes are made, the crisis in cancer services will continue to grow, and patients will continue to pay the price.

King Charles’ Cancer Treatment Shows Steady Progress, To Extend Into Next Year

December 20, 2024, 5:44 pm

King Charles’ cancer treatment is progressing positively and will extend into next year, according to a Buckingham Palace insider. This update comes as the royal family prepares for their annual Christmas gathering after what has been described as a “brutal” year.

The 76-year-old monarch, who ascended the throne in 2022, was diagnosed with an unspecified cancer earlier this year. The condition was identified during tests following a procedure to address an enlarged prostate in February. Despite returning to public duties two months later, his activities have been scaled back on medical advice, which has been challenging for the king, known for his tireless work ethic.

“His treatment has been moving in a positive direction, and as a managed condition, the treatment cycle will continue into next year,” a palace source stated. The insider clarified that there has been no deterioration in Charles’ health and that the extension of his treatment into 2025 does not indicate any significant developments.

The king has maintained a busy schedule, culminating in a visit to Walthamstow, northeast London, a community that held a large counter-protest in August amid national riots. In October, Charles and Queen Camilla briefly visited India to stay at a holistic health center, following a major overseas tour to Australia and Samoa.

Also Read: King Charles Spreads Christmas Cheer With Tourists In London | WATCH

The past year has brought several challenges for the royal family. In March, it was revealed that the Princess of Wales, Kate, was undergoing preventative chemotherapy. Though her treatment has ended, her return to duties has been slow. Prince William described the year as “brutal” for the family.

Beyond health concerns, the family faced additional controversies. Prince Andrew was linked to a scandal involving an alleged Chinese agent, and scrutiny over royal finances intensified. Meanwhile, Prince Harry remains estranged from the family, with more revelations expected as he continues legal battles in the UK. Both Harry and Andrew are expected to miss the Christmas gathering at Sandringham, highlighting the tensions within the family.

Virologist Cures Her Own Cancer With Lab-Grown Viruses, Sparks Ethical Debate

November 8, 2024, 10:12 pm

In a groundbreaking case of self-experimentation, virologist Beata Halassy treated her stage 3 breast cancer by injecting lab-grown viruses directly into her tumor. The treatment, known as oncolytic virotherapy (OVT), helped shrink her tumor and ultimately led to a successful surgical removal. Halassy has been cancer-free for four years.

What Is Oncolytic Virotherapy?

Oncolytic virotherapy uses viruses to attack cancer cells and trigger the immune system to fight the disease. Although OVT is still experimental, one agent, T-VEC, has been approved in the U.S. for treating metastatic melanoma. However, there are no approved OVT treatments for breast cancer.

Halassy’s Bold Experiment

Unable to face another round of chemotherapy, Halassy used her virology expertise to cultivate two viruses—measles and vesicular stomatitis virus (VSV)—to target her tumor. Over two months, she self-administered the viruses with the help of a colleague, under the supervision of her oncologists.

(Credit: Ivanka Popić)

The results were promising: the tumor shrank, softened, and detached from surrounding tissues, making it easier to remove. Post-surgery analysis showed a strong immune response, indicating the treatment worked as intended.

Ethical Concerns

Halassy’s self-experimentation has sparked ethical debates. Critics warn that publishing her success might encourage others to bypass conventional treatments in favor of risky, unproven methods. Legal and medical ethics expert Jacob Sherkow notes that while her actions may be ethical, they should not serve as a model for cancer patients without specialized knowledge.

A New Research Focus

Halassy’s experience has shifted her research priorities. She now investigates OVT’s potential to treat cancer in domestic animals, thanks to new funding. Reflecting on her journey, she believes her case highlights the potential of OVT while emphasizing the importance of ethical considerations in self-experimentation.

Halassy’s story is a testament to the innovative spirit of scientific research, but it also serves as a reminder of the ethical boundaries that should guide such bold experiments.

The Real Reason Behind King Charles Cancer Treatment Pause Revealed

October 7, 2024, 2:24 pm

King Charles is set to take a temporary break from his cancer treatment as he embarks on a major royal visit to Australia and Samoa, his first trip to a Commonwealth Realm as monarch. The 75-year-old king, who was diagnosed with cancer earlier this year, received approval from his doctors to pause his treatment for 11 days.

The royal tour, beginning on October 18, will see King Charles and Queen Camilla visiting Sydney and Canberra before attending the Commonwealth Heads of Government Meeting (CHOGM) in Samoa. With a demanding schedule of up to 10 engagements per day and only one rest day, the king will be accompanied by a medical team to ensure his well-being during the trip.

King Charles was diagnosed with an undisclosed form of cancer following prostate surgery in February and has been undergoing weekly treatment since. Buckingham Palace has remained tight-lipped about further details regarding his condition. Despite the ongoing treatment, the king has gradually returned to his royal duties in the UK.

Additionally, King Charles has adjusted his daily routine at the advice of his doctors, including introducing lunch into his diet, a meal he had previously avoided. Now, with encouragement from Queen Camilla, he includes small snacks, such as half an avocado, to maintain energy while managing his illness.

While King Charles attends to his royal obligations, his son, Prince Harry, is conducting his own diplomatic efforts, traveling between New York and Lesotho. Focusing on charitable causes dear to both him and his late mother, Princess Diana, Prince Harry is doing so without the presence of his wife, Meghan, who is engaged with her business in California.

Kate Middleton Steps Out in Public for the First Time After Cancer Treatment

September 23, 2024, 12:17 pm

Kate Middleton was seen in public for the first time post her chemotherapy treatment. She attended a church service along with her husband, Prince Williams as well as King Charles III and Queen Camilla near their Balmoral estate in Scotland. She was spotted in the passenger seat of a car driven by the Prince Of Wales. As for his attire, he opted for a navy blue suit with a matching tie. This event marked her return to public duties after a significant absence due to her cancer treatment.

The Princess Of Wales announced that she had completed the chemo treatment for an ‘undisclosed type of cancer’ on September 9, shortly after Buckingham Palace released news that King Charles III was also getting treatment of cancer. Kate expressed optimism about her recovery, noting that her journey to full health would be gradual and that she plans to participate in limited engagements through the end of the year.

“The last nine months have been incredibly tough for us as a family,” Kate shared in a video. “Life as you know it can change in an instant, and we have had to find a way to navigate the stormy waters. The cancer journey is complex, scary and unpredictable for everyone, especially those closest to you. It brings a new perspective on everything.”

Previous Public Appearances:

Kate resumed her royal duties earlier this week. She held a private meeting with the team members from Kensington Palace and the Centre for Early Childhood at Windsor Castle since March. During her cancer treatment, the princess made two public appearances: In June, she participated in the Trooping the Colour military parade for King Charles’ birthday, and in July, she attended the men’s final at Wimbledon, where she received a standing ovation from the crowd.

UK Patient Becomes First To Receive Groundbreaking Lung Cancer Vaccine; Here’s How It Works

August 23, 2024, 12:05 pm

A 67-year-old lung cancer patient in the UK, Janusz Racz, has become the first to receive a new experimental vaccine designed to help his body combat the life-threatening disease. This groundbreaking vaccine, codenamed BNT116 and manufactured by BioNTech, utilizes the same mRNA technology that was the foundation of its highly effective COVID-19 vaccine. Administered at the University College London Hospital, the vaccine is seen as a more precisely targeted treatment compared to chemotherapy, with doctors expecting it to have less collateral damage on healthy cells.

“It’s painless,” Racz told Sky News after receiving his first dose. “It’s much better than chemo, which was hard for me,” he added. The vaccine was delivered through at least six syringes, each containing genetic material for different parts of the tumor, to train five billion cells in his immune system to go on the attack.

The vaccine works by presenting common tumor markers to the patient’s immune system using mRNA technology. This approach helps train the immune system to recognize and fight cancer cells expressing these markers and potentially eliminate cells that suppress the immune response. According to doctors, the vaccine can flag key components of the tumor as a threat, prompting the body to obliterate cancer cells wherever they are, which could reduce the tumor size and lower the risk of recurrence.

More than 100 patients with non-small cell lung cancer will participate in the trial. “If I was the hundredth or the first [study volunteer], it does not matter to me. I believe it will help me – and help other people if the vaccine goes into production faster. COVID-19 vaccines helped millions of people. This will also help millions of people,” said Racz.

The trial will also aim to identify any major side effects before larger studies are conducted to establish the vaccine’s clinical effectiveness. Volunteers are expected to receive dozens of doses over 12 months to boost their immune systems.

Non-small cell lung cancer, the most common type of lung cancer, tends to grow slowly but often spreads to other parts of the body before it is diagnosed, making early detection and treatment essential. Most cases, though not all, are linked to smoking. Unfortunately, many patients are diagnosed at an advanced stage when treatment is less effective, and currently, only about a quarter survive for five years. The NHS has begun screening older smokers for lung cancer in hopes of catching cases earlier. Anyone experiencing symptoms like a persistent cough, chest pain, or fatigue should see a doctor immediately.

Kate Middleton Re-evaluates Royal Duties Amid Cancer Treatment, Future Uncertain

August 17, 2024, 1:15 pm

Kate Middleton, the Duchess of Cambridge, is reportedly re-evaluating her royal duties as she navigates her ongoing cancer treatment. Her recent appearance at Trooping the Colour sparked excitement among fans, but concerns about her future role within the royal family have grown as she continues her health battle.

Public Appearance Sparks Hope

In July, Kate’s presence at Wimbledon was seen as a sign of her potential recovery and return to royal duties. Her appearance was warmly received, giving hope that she might soon resume her full responsibilities. However, sources close to the Duchess have revealed that she is still facing significant health challenges, leading her to reconsider her role.

Insider’s Perspective on Kate’s Health and Duties

Royal biographer Robert shared insights into Kate’s current situation, urging the public to manage their expectations regarding her return. He emphasized that while Kate is making progress in her recovery, it is unlikely that she will return to her full-time royal duties anytime soon.

“She’s going to have to pick and choose how she completes her comeback, if there is a comeback in that form at all,” Robert stated. He also highlighted that Kate’s health journey has led her to realize the importance of life’s most precious aspects, particularly her family.

Prioritizing Family Over Royal Duties

For Kate and Prince William, their three children remain their top priority. The biographer noted that the Duke of Cambridge has been deeply affected by the challenges facing his family, including his father’s health and Kate’s diagnosis. He added, “They have the right to decide how they want to move forward. Catherine will be prioritizing her children and supporting William.”

The Crown’s Reaction to Kate’s Decision

Kate’s potential decision to step back from her royal duties will undoubtedly prompt a strong reaction from the Crown. However, the royal family is expected to support her choice, recognizing her importance both to the family and to the public. As Robert put it, “The Royal Family will have to dance to her tune rather than the other way around.”

Kate Middleton’s journey serves as a reminder of the personal sacrifices often made by public figures, and her decision, whatever it may be, will be met with respect and understanding from her supporters around the world.

Health Sector Welcomes New Union Budget Allocation

July 23, 2024, 6:26 pm

NEW DELHI: The allocation to health sector has been welcomed by major health care centres across the country The budget adopts a community-centric approach, prioritizing the needs of the “Garib” (Poor), “Mahilayen” (Women), “Yuva” (Youth), and “Annadata” (Farmer). A significant and positive development for the healthcare industry is the Union Budget’s emphasis on reducing the cost of medications, particularly for cancer patients. The Central government has designated Rs 89,287 crore for the development, maintenance, and enhancement of India’s healthcare system, a slight increase from Rs 88,956 crore in FY24.

Reacting over the budget Dr Shyam Aggarwal , Chairman , Medical Oncology, Sir Ganga Ram Hospital said ” All imported life saving drugs are costly and customs duty exemption is welcome step. Cancer drugs are very expensive and life saving. Patients require long term treatment. All steps to bring the cost down are more than welcome. Deruxtecan drug is breast cancer drug and can be used in all cancers with Her2 positive gene Osimertinib Is lung cancer drug for egfr mutation Durvalumab Is drug for lung and biliary tract cancers. All these cancers are quite common in India and detected in late stages in our Country.”
Meanwhile Dr. Harsh Mahajan, Founder & Chairman, Mahajan Imaging &Labs and Chairman FICCI Health Services Committee said “Exemption of three life saving medicines for cancer treatment is a welcome step. We will need to study the fine print to know what these drugs are. Exemption of customs duty on components of Xray tubes and digital detectors, will lead to spurring of indigenous manufacturing of digital Xray machines in India. Allocation of funds for innovation and skilling will also help those who are working in the healtcare sector”

“We commend the government’s commitment to improving healthcare, as highlighted in the Union Budget 2024. The changes in Basic Customs Duty (BCD) for X-ray tubes and flat panel detectors used in X-ray machines under the phased manufacturing program are highly appreciated. Synchronizing these changes with domestic capacity addition will bolster our diagnostic capabilities and promote the growth of the domestic medical device industry. These measures reflect a comprehensive strategy to enhance India’s healthcare infrastructure and patient care” said Mr. Behram Khodaiji, CEO of Ruby Hall Clinic on the Union Budget

Having similar views on Union budget Dr. Vaibhav Kapoor, Co-founder, Pristyn Care reacted on the budget stating that “The Union Budget for 2024-25 is a positive growth step and we welcome it wholeheartedly. We are glad to see that efforts have been made to back education and skills development such as by revising the Model Skill Loan Scheme enabling 25,000 students per annum and giving E-vouchers for loans up to Rs 10 lakh to one lakh students yearly. The new package announced today includes five schemes with a budget of Rs 2 lakh crore aimed at generating employment opportunities and enhancing skill levels of 4.1 crores youth over the next five years. In addition, this year’s allotment of Rs 1.48 lakh crore towards education, employment and skilling demonstrates strong commitment in these areas. These will help young people to have better education, improve the education system through investing heavily in it and create many job opportunities. This whole approach will make our future brighter, healthier and more prosperous for everybody.

BCCI Urged To Fund Ex-Coach Gaekwad’s Cancer Treatment After ₹125 Crore T20 Win Bonus

July 2, 2024, 5:13 pm

As the Board of Control for Cricket in India (BCCI) announced a substantial Rs. 125 crore reward for the Indian team following their 2024 T20 World Cup victory, there have been calls to support the treatment of former Indian cricketer and head coach Anshuman Gaekwad. Gaekwad, who led India during two periods in the late 1990s, is currently battling blood cancer at King’s College Hospital in London at the age of 71. Sandeep Patil, former BCCI chairman of selectors and Gaekwad’s teammate, has been the most vocal in urging the BCCI to assist.

“Anshuman Gaekwad told me that he has received financial support from the cricket board, but more financial support is needed,” wrote Sandeep Patil in his Mid-Day column.

Patil mentioned that he had discussed the matter with BCCI treasurer Ashish Shelar, who assured assistance.

“In this regard, former cricketer Dilip Vengsarkar and I had a conversation with Cricket Board Treasurer Ashish Shelar. We called Ashish Shelar from the car after seeing Anshuman Gaekwad in the hospital,” Patil wrote.

“Ashish Shelar instantly said he would look into ours and other former cricketers’ requests for funds. I’m sure he will facilitate this and, at the risk of sounding macabre, save Anshu’s life. Any cricketer from any country should be helped by his Board, but Anshu’s case must be taken up on priority and treated as paramount,” Patil added.

Gaekwad, who played 40 Tests and 15 ODIs for India between 1974 and 1987, served as India’s head coach from 1997 to 1999 and again after the match-fixing scandal. During his second tenure, India finished runners-up to New Zealand in the 2000 ICC KnockOut Trophy, later known as the Champions Trophy.

Patil also highlighted in his column that Sachin Tendulkar was in top form during Gaekwad’s tenure as head coach.

Kate Middleton’s Discreet Trip To US For Her Cancer Treatment

June 21, 2024, 5:08 pm

Kate Middleton, the Princess of Wales, reportedly is undergoing undisclosed cancer therapy in Houston, Texas.

“She might be the Princess of Wales, but she is still a mother and wife and going through the same set of emotions and worries and fears as anyone else in that set of circumstances would be,” Queen Elizabeth’s former press secretary, Ailsa Anderson, told People.

Kate Middleton, a reassuring presence for her fans, stood strong at King Charles III’s birthday parade, Trooping the Colour ceremony, despite her ongoing battle with cancer.

The Princess of Wales appeared for the first time since her cancer diagnosis was a show of strength, another insider claimed, “The treatment is punishing, and it is different for different people. And the side effects can be unforgiving.”

Did Kate’s alleged sighting in Houston cause her to miss her Trooping the Colour audition?

One Redditor claimed to be “visiting friends at the St. Regis and they spoke about her being at the hotel.”

An online sleuth reported that a University of Texas MD Anderson Cancer Center staff member saw Kate “hiking and laughing with her bodyguard” near the hospital. MD Anderson is renowned for its expertise in various cancers like breast, ovarian, lung, prostate, melanoma, and leukemia.

Life & Style earlier cited a source, “There are multiple witnesses who claim to have seen her in Texas.” “It’s believed she’s flying back and forth for secret cancer treatment there.”

It was previously noted that Pope Francis’ medical team from Rome’s renowned Gemelli Clinic reportedly traveled to London in January to conduct the Princess’ abdominal surgery.

Just days before the monarch’s birthday parade, Kate released a statement giving an update on her health: “I am making good progress, but as anyone going through chemotherapy will know, there are good days and bad days.”

“On those bad days, you feel weak and tired, and you have to give in to your body resting. But on the good days, when you feel stronger, you want to make the most of feeling well.”

“My treatment is ongoing and will be for a few more months,” she concluded. However, Kate didn’t reveal the type of cancer she was diagnosed with.

Kate Middleton, Prince William Not To Meet Prince Harry During Their Visit To UK: Source

May 1, 2024, 3:41 pm

Kate Middleton and Prince William have reportedly decided not to meet Prince Harry during his upcoming visit to the UK next week, the couple’s friends told The Daily Beast. They don’t want to add extra tension as the Princess of Wales is already stressful for cancer treatment, according to reports.

“Everyone now clearly understands each other’s position,” the couple’s acquaintance remarked. Harry’s narrative, according to Spare, “completely betrayed William and Catherine.” They don’t chat to Harry and Meghan, and they have no intention of doing so when Catherine is most vulnerable.

It was reported that Harry reached out to Kate privately after her cancer diagnosis. However, a friend who was initially close to both Harry and William but is no longer in touch with Harry dismissed the idea that Harry’s well wishes could mend relations.

Harry is expected to return to the UK for a church service commemorating the tenth anniversary of the Invictus Games, but Meghan Markle will not accompany him.

Friends of Kate and William have previously expressed their desire for peace and quiet, stating that “A visit from Harry, with all the drama that would bring, would be the opposite of that.”

“They have come to terms with the estrangement from Harry, and are content to let sleeping dogs lie,” another friend said

Indian-Origin Teen Gets “Life-Changing” Cancer Treatment in UK

March 31, 2024, 12:12 pm

Yuvan Thakkar, an Indian-origin teenager diagnosed with cancer, says he is now able to enjoy the things he loves after life-changing treatment thanks to a fund set up by the UK’s state-funded National Health Service to make innovative therapies accessible to thousands of patients.

According to NHS England, 16-year-old Mr Thakkar from Watford near London was the first child in the UK to benefit from a pioneering CAR T therapy called tisagenlecleucel (Kymriah) thanks to its Cancer Drugs Fund (CDF).

It comes as the National Health Service (NHS) marks a milestone this weekend of 100,000 patients benefitting from early access to the latest and most innovative treatments with the help of CDF. The undisclosed cost of such treatments is covered by the fund.

“My life has changed so much since I received the CAR T therapy,” said Mr Thakkar, who thanked Great Ormond Street Hospital (GOSH) in London for the “incredible” care he received.

“I remember I had to take so many trips to hospital and had long periods out of school… They have helped me recover to a state where I am able to enjoy so many things I love doing, such as playing snooker or pool, meeting friends and family, and going on wonderful holidays. It’s hard to imagine how things would have been if the treatment wasn’t available,” he said.

Mr Thakkar, diagnosed with a form of leukaemia aged six, received a treatment which modifies a person’s immune cells to recognise and attack cancer cells.

His treatment began in 2019, when he was 11 years old after he relapsed following other treatments such as chemotherapy and a bone marrow transplant. His mother Sapna said the family had received a “second chance” at life since the success of the treatment. Without the fast-track access available through the CDF, the 45-year-old said there may have been no other way for her son to receive the life-saving treatment.

“It felt like our prayers were finally answered. We still feel so grateful for this chance that’s been given to us and not a single day passes by when we haven’t felt thankful for all the doctors and nurses that have helped us through this long and difficult journey,” said Sapna Thakkar.

The CDF, which opened in its current form in July 2016, is used by NHS England to provide fast-tracked access for patients to all new cancer treatments approved by the National Institute for Health and Care Excellence (NICE), in addition to gathering further evidence of long-term effectiveness for promising drugs. It allows faster access to more than 100 drugs to help improve, extend or – in some cases – save their lives.

“Treating 100,000 cancer patients in England with innovative treatments through the Cancer Drugs Fund is a fantastic milestone for the health service to reach, and testament to the hard work of oncologists and their teams across the country,” said Professor Sir Stephen Powis, NHS national medical director.

“This vital fund is helping ensure patients get access to the most promising drugs far quicker than would otherwise be the case, helping people with cancer like Yuvan receive a life-changing intervention that sets a path for a longer, healthier life spent with family and friends,” he said.

The fund benefits people with common cancers, such as breast, lung, colorectal and prostate, as well as those with less common cancers, such as ovarian, cervical, kidney, skin, myeloma, lymphoma and leukaemia, and rare cancers, including thyroid and biliary tract.

The current CDF budget of GBP 340 million is 70 per cent more than the previous CDF and is used alongside NHS England’s Innovative Medicines Fund of GBP 340 million, which the health service said means a total of GBP 680 million is ringfenced for fast-tracking new medicines.

ROLE OF IMMUNOMODULATION IN CANCER TREATMENT – THE DAWN AND THE FUTURE

February 14, 2023, 1:16 pm

Immunomodulation, the manipulation of the immune system complex to enhance its response against cancer cells, has emerged as a promising strategy in the management of cancer.

The ability of the immune system to recognize and target cancer cells is dependent on the presence of specific molecules, called antigens, on the surface of cancer cells. Immunomodulation aims to enhance the immune response against these antigens, thereby increasing the ability of the immune system to target and destroy cancer cells.

Immunomodulation has the potential to be combined with the existing chemotherapy drugs to enhance cancer cell kill. It can also be used alone (without concomitant chemotherapy) to bring about durable cancer control of metastatic cancers. We are already seeing some of these benefits in our clinical practise today. We are delighted to see significantly increased cure rates of not only early stage but also of advanced stage 4 cancers.

There have been varied strategies that have been explored for Immunomodulation.

Monoclonal Antibodies and Immune checkpoint inhibitors:

One of the most promising approaches to immunomodulation in cancer management is the use of special drugs (also called immune checkpoint inhibitors) which are already in widespread use for the treatment of many common cancers, including blood cancers.

These drugs target specific molecules, called “checkpoint” molecules (antigens) that act as brakes on the recognition apparatus of the immune response. By inhibiting these checkpoint molecules, immune checkpoint inhibitors release the brakes on the immune response and allow the immune system to target and destroy cancer cells. With these drugs we have not only been able to control many stage 4 cancers but also cure a few of them. There is a lot of exciting data coming up suggesting that Immune checkpoint inhibitors may be enable us to save critical organ function as was promisingly shown recently in a few patients with rectal cancer due to the use of Dostarlimab.

Non-Specific Immunotherapies

They are non-specific Immunomodulators which boost the existing immune response and destroy cancer cells. This is achieved through increasing the levels of Immuno-messengers called cytokines which send messages between the cells of the immune system and lead to increased tumor cell kills. This type of Immunomodulation has led to serious side effects in the past due to which increased research is underway to not only increase the effects but also reduced the side effects of this type of immunomodulation.

Oncolytic virotherapy: Using viruses to target cancer cells

Oncolytic virotherapy is a specialized immunomodulation approach which uses genetically modified version of viruses to specifically target and destroy cancer cells. These viruses infect and exponentially multiply inside the cancer cells causing the tumor cells to swell and burst, thereby killing the cancer cells. When the cancer cells die, their antigenic protein contents are released that stimulate the immune response against cancer cells. The Virus typically does not enter the normal cells. Oncolytic virotherapy has been approved for the treatment of Melanoma (Skin cancer) and is being seen to be effective in the management of various types of cancer, including breast cancer and ovarian cancer.

Cancer vaccines: Stimulating the immune response against cancer cells

Another promising approach is the use of cancer vaccines. There are vaccines that help to prevent cancers such as Cervical Cancer and liver cancer and there are vaccines that treat cancers. The latter types are designed to stimulate the immune system to recognize and target specific antigens on cancer cells. This can be achieved through the use of whole cancer cells, cell lysates, or specific antigens. Cancer vaccines have been approved for the treatment of advanced prostate cancers and shown to be effective in the management of various types of cancer, including melanoma and ovarian cancer.

Adoptive cell therapy: Increasing the number of immune cells targeting cancer cells

Adoptive T-cell therapy (ACT) is another promising and highly exciting approach to immunomodulation in cancer management. T lymphocyte cells are specific immune cells that have the ability to recognize and target cancer cells. In this approach, the patient’s normal T cells are isolated and removed from the blood and are genetically altered so as to recognize cancer cells avidly. Thereafter these altered T cells are multiplied in number outside and put back into the body after which they destroy all the cancers cells in a robust fashion. This type of therapy has also been popularly named as chimeric antigen receptor T cell therapy (CAR-T therapy). ACT has been shown to be effective in the management of various types of cancer, including melanoma, leukemia, and ovarian cancer.

Side effects of immunomodulation in cancer management

While Immunomodulation in cancer management is highly specific and robust, several side effects have been encountered which are largely mild in nature. These include fatigue, rash, and diarrhoea. Flu-like symptoms are common after the initial few infusions which largely wane away with time. Sometimes, immunomodulation can lead to an overactive immune response, called as the cytokine storm, which can lead to serious side effects, such as fever, chills, and difficulty breathing which rarely may lead to organ failure or death as well. The key in utilizing Immunomodulation as the mainstay of cancer therapy would be by carefully selecting patients with adequate medical fitness to tolerate this treatment approach and making sure to monitor these patients closely during therapy.

Potential benefits and risks of immunomodulation in cancer management

In conclusion, immunomodulation has emerged as a an exciting and promising strategy in the management of various solid cancers and blood cancers with various approaches being investigated, such as immune checkpoint inhibitors, cancer vaccines, adoptive cell therapy, and oncolytic virotherapy. However, it is important to be aware of the potential side effects associated with these therapies and to closely monitor patients for any adverse reactions. Medical oncologists with experience utilizing these approaches fully understand the potential benefits and risks of these therapies. Many including yours truly believe, that immunomodulation will not only enhance the benefits but also reduce the limitation of currently existing cancer treatment options.

Dr. Mangesh P Kamath, Consultant Oncology, Fortis Hospital, Bannerghatta Road, Bengaluru